Bristol Myers Squibb’s (BMS) Opdualag (nivolumab-relatlimab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line treatment of advanced melanoma in patients aged 12 years and older.
Publications
NICE Approves Nivolumab and Relatlimab Combination for Advanced Melanoma Treatment
The National Institute for Health and Care Excellence (NICE) has made a significant stride in the management of advanced melanoma by approving the drug combination of nivolumab and relatlimab as a first-line treatment.
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma.
FDA Fast Tracks Naporafenib for Unresectable, Metastatic Melanoma
The Phase III SEACRAFT-2 trial will analyze the clinical efficacy of naporafenib compared with physician’s choice of single-agent dacarbazine, temozolomide, or trametinib among patients with NRAS-mutated metastatic melanoma who received prior treatment with an immunotherapy.